Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Hemostemix Inc V.HEM

Alternate Symbol(s):  HMTXF

Healthcare Biotechnology
Hemostemix Inc. is a Canada-based clinical-stage biotechnology company. The Company’s principal business is to develop, manufacture and commercialize blood-derived stem cell therapies to treat various diseases. It is an autologous stem cell therapeutics company that holds 91 patents on the derivation of three stem cell lineages from the patient’s blood, including angiogenic cell precursors (ACP... see more

Recent & Breaking News (TSXV:HEM)

Hemostemix Files Its Unaudited Condensed Consolidated Interim Financial Statements and Management Discussion and Analysis for the Three Months Ended March 31, 2020

Newsfile July 13, 2020

Hemostemix Files Its Audited Annual Financial Statements and Management Discussion and Analysis for the Period Ending December 31, 2019

Newsfile July 10, 2020

Hemostemix Announces Closing of Private Placement

Newsfile July 9, 2020

Delaware Court Grants An Order for the Expedited Briefing Schedule of Hemostemix's Injunction against Accudata Solutions, Inc. and Hemostemix is in Receipt of an Unsigned Report from Aspire Health Science

Newsfile July 6, 2020

Hemostemix Filed an Injunction Against Accudata Solutions, Inc. for the Return of its Clinical Trial Midpoint Report and Data

Newsfile July 3, 2020

Hemostemix Appeals Alberta Court's Service Ex Juris Decision

Newsfile June 24, 2020

Stem Cell Innovators See Clinical Success in $250 Billion Ischemia Market

Stockhouse Editorial June 22, 2020

Hemostemix Announces $700,000 Non Broker Private Placement, Update on its Proceedings against Aspire Health Science, LLC

Newsfile June 19, 2020

Hemostemix Announces Delay in Filing of Annual Financial Statements and Application for Management Cease Trade Order

Newsfile June 16, 2020

Hemostemix Announces Aspire Health Science, LLC Has No Right to Manufacture or to Sublicense Hemostemix's Intellectual Property

Newsfile June 8, 2020

Hemostemix Announces Dr. Mary Argent-Katwala as Its Clinical Trial Manager

Newsfile June 3, 2020

Hemostemix Announces Injunction Hearing Against Aspire Health Science, LLC

Newsfile June 3, 2020

Hemostemix Announces Private Placement and Provides Debt Settlement Update

Stockhouse.com May 19, 2020

Hemostemix Moves to Consolidate Shares

Stockhouse Editorial May 8, 2020

Hemostemix Announces Annual Special Meeting Results

Newsfile May 7, 2020

Hemostemix Announces Closing of Private Placement

Newsfile May 7, 2020

Hemostemix Taps Former Cabinet Minister to Board of Advisors

Stockhouse Editorial April 30, 2020

Hemostemix Announces the Appointment of David Tsubouchi to its Board of Advisors

Newsfile April 30, 2020

Hemostemix Announces Private Placement and Debt Settlement Update

Newsfile April 29, 2020

Hemostemix Announces the Appointment of Timothy Chang to Board of Advisors

Newsfile April 21, 2020